StemCell Therapy

CTI was named the winner of the Vision Award category, which was awarded to the organization for inspiringand deliveringnew thinking to the marketplace and for showcasingNorthern Kentucky as an area of thoughtful, innovative industry leaders.

"We're honored to be recognized by the Northern Kentucky Chamber of Commerce with this award for CTI's continued successes and innovations," according to Timothy J. Schroeder, Founder and CEO.

CTI Clinical Trial and Consulting Services (CTI), a global, privately held, full-service contract research organization announces the acquisition of Eurotrials, a full-service contract research organization, with more than 20 years of experience, and strong local expertise in Europe and Latin America.

CTI is extremely happy to partner with Bexion on the development of this novel therapy in patients who desperately need alternative treatments, stated William Aronstein, PhD, MD, FACP, Vice President, Medical Affairs at CTI. They are an innovative organization with very strong regional ties the drug was initially developed and licensed at a local hospital, early funding has predominantly come from the region, and the management and board have strong local connections.

The expansions in Taiwan and Japan are part of continued efforts to increase capacity for clinical research across Asia, according to Patrick Earley, Vice President, International. We have been working across Asia for a number of years, but felt like a more permanent presence in Taipei and Tokyo would further enhance relationships with local medical centers and biotechnology companies."

More here:
CTI - CRO Specializing in Clinical Research and Consulting

This entry was posted on June 21, 2018 at 5:42 pm and is filed under Regenerative Medicine. You can follow any responses to this entry through the RSS 2.0 feed. Both comments and pings are currently closed. |